NovelStem International Corp. reported its financial results for the first quarter of 2026, revealing a net loss of approximately $55,021, a significant improvement compared to a net loss of $207,216 in the same period of 2025. The company’s total operating expenses decreased to $4,953 from $94,574 year-over-year, primarily due to reduced general and administrative costs. Interest expenses also saw a decline, falling to $50,068 from $112,642, reflecting the settlement of a litigation funding agreement in May 2025.
As of March 31, 2026, NovelStem's current assets increased to $100,912 from $15,786 at the end of 2025, largely attributed to the issuance of common stock that generated $250,000 in cash. Conversely, total liabilities decreased to $2,047,588 from $2,157,441, driven by a reduction in accounts payable and the repayment of short-term borrowings. The company’s accumulated deficit rose slightly to $294,035,992 from $293,980,971, indicating ongoing challenges in achieving profitability.
Strategically, NovelStem has undergone significant changes, including the liquidation of its former investment in NewStem Ltd. in August 2025, which had focused on developing cancer treatment technologies. The company has since shifted its focus to monetizing the rights to the intangible assets from NewStem, now held by Yissum, and is exploring potential merger or acquisition opportunities. The company’s equity structure also changed, with the issuance of 2,450,980 shares during the quarter, increasing the total shares issued to 52,767,652.
Operationally, NovelStem's management is actively pursuing additional funding to support ongoing operations, with plans to monetize its remaining assets. The company has entered into various financing agreements, including a bridge loan from its Executive Chairman and short-term notes payable, to address its liquidity needs. As of the latest filing, the company is in negotiations with debt holders to convert their debt into equity, which could further stabilize its financial position.
Looking ahead, NovelStem's management remains cautious but optimistic about its ability to secure additional financing and successfully monetize its assets. However, the company acknowledges that its future operations depend heavily on the successful commercialization of its remaining intangible assets and the continued support from shareholders. The ongoing efforts to improve profitability and manage liabilities will be critical as NovelStem navigates its path forward in the biotech sector.
About NovelStem International Corp.
NovelStem International Corp. is a holding company focused on biotech investments, primarily owning interests in NewStem Ltd., an Israeli biotech developing stem cell-based diagnostics and therapeutics, and a joint venture in entertainment properties. The company’s core activities involve managing biotech assets, licensing technology, and pursuing innovative medical research. It relies on investments and strategic partnerships, with a focus on advancing regenerative medicine and cancer diagnostics.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.